Literature DB >> 18774459

Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer.

Seth P Lerner1, Steven Shen.   

Abstract

The prostate is commonly involved by transitional cell carcinoma (TCC) in patients with bladder cancer. A number of clinicopathologic factors including multifocal carcinoma in situ, tumor location, and tumor stage are associated with prostatic TCC (pTCC). In addition, the manner and extent of pathologic examination also makes a significant difference in the detection rate. Distinct patterns and extent of pTCC have been described and are associated with pathologic stage of the primary bladder tumor as well as prognosis. Preoperative transurethral biopsy of the prostatic urethra is a sensitive and accurate method to detect pTCC and is helpful for surgical planning. Given the high incidence of pTCC and prostatic adenocarcinoma, radical cystoprostatectomy is the treatment of choice for loco-regional control for patients with T4a disease. Further studies are necessary to establish the role of neoadjuvant and adjuvant therapy for patient with prostatic stroma invasion.

Entities:  

Mesh:

Year:  2008        PMID: 18774459     DOI: 10.1016/j.urolonc.2008.03.002

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  5 in total

1.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

2.  Transurethral biopsy of the prostatic urethra is associated with final apical margin status at radical cystoprostatectomy.

Authors:  Friedrich-Carl von Rundstedt; Douglas A Mata; Steven Shen; Yi Li; Guilherme Godoy; Seth P Lerner
Journal:  J Clin Urol       Date:  2016-11-02

3.  Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version.

Authors:  Bimal Bhindi; Ronald Kool; Girish S Kulkarni; D Robert Siemens; Armen G Aprikian; Rodney H Breau; Fadi Brimo; Adrian Fairey; Christopher French; Nawar Hanna; Jonathan I Izawa; Louis Lacombe; Victor McPherson; Ricardo A Rendon; Bobby Shayegan; Alan I So; Alexandre R Zlotta; Peter C Black; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2021-08       Impact factor: 1.862

4.  Full analysis of the prostatic urethra at the time of radical cystoprostatectomy for bladder cancer: impact on final disease stage.

Authors:  Justine Varinot; Philippe Camparo; Morgan Roupret; Marc Olivier Bitker; Fréderique Capron; Olivier Cussenot; J Alfred Witjes; Eva Compérat
Journal:  Virchows Arch       Date:  2009-10-20       Impact factor: 4.064

5.  Detection of Incidental Prostate Cancer or Urothelial Carcinoma Extension in Urinary Bladder Cancer Patients by Using Multiparametric MRI: A Retrospective Study Using Prostate Imaging Reporting and Data System Version 2.0.

Authors:  Sang Eun Yoon; Byung Chul Kang; Hyun-Hae Cho; Sanghui Park
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2020-05-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.